RHHVF

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Roche Holding AG

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
CEO
Severin Schwan
Employees
0
Headquarters

Grenzacherstrasse 124
Basel, Basel-Stadt (Basle
Phone: 41.61.688.11.11
http://www.roche.com

News

Morgan Stanley bearish on Roche stock eyes obesity data
Jul 12, 2024 08:50am

https://www.investing.com/news/company-news/morgan-stanley-bearish-on-roche-stock-eyes-obesity-data-93CH-3516926


Source:Investing.com
Zydus barred from selling cancer biosimilar, for now
Jul 10, 2024 18:21pm

The Delhi High Court has temporarily barred Zydus Lifesciences from selling its breast cancer drug Sigrima, a biosimilar of Roche''s Perjeta (pertuzumab), due to a patent infringement lawsuit filed by Roche. The court granted an interim injunction against Zydus after Roche argued that Sigrima and another biosimilar, Womab from Dr Reddy''s, violate its patents. Zydus had received conditional approval for its pertuzumab biosimilar but launched it amidst ongoing litigation, prompting the court to intervene to prevent potential market disruption.


Source:Economic Times India
Roche wins CE mark for its first CGM
Jul 10, 2024 17:59pm

Dive Brief: Roche said Tuesday it has received a CE mark for its Accu-Chek Smartguide continuous glucose monitor (CGM). The clearance positions Roche to challenge Abbott and Dexcom for the European CGM market. Roche plans to start selling the device “in …


Source:EIN News Pharmaceuticals
Remix Therapeutics Attains Near-Term Milestone from Roche Collaboration
Jul 10, 2024 11:00am

The collaboration leverages Remix''s REMaster platform to discover novel drugs for a diverse range of target classes Remix is eligible to receive up to $1 billion in milestone payments and royalties WATERTOWN, Mass., July 10, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a…


Source:PR Newswire
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution
Jul 09, 2024 11:04am

Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes …


Source:EIN News Pharmaceuticals
Roche Obtains CE Mark For AI-enabled Continuous Glucose Monitoring Solution
Jul 09, 2024 05:36am

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) said that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution. It provides 14 days of accurate real-…


Source:Finanz Nachrichten
F. Hoffmann-La Roche Ltd: Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
Jul 09, 2024 05:10am

The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy.The built-in AI-trained a…


Source:Finanz Nachrichten
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
Jul 09, 2024 05:00am

The Accu-Chek SmartGuide CGM solution provides 14 days of accurate1 real-time glucose values for adults living with type 1 and type 2 diabetes on flexible insulin therapy. The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur. The solution is set to launch in selected Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes | RHHBY Stock News
Jul 09, 2024 05:00am

Roche''s Accu-Chek SmartGuide CGM receives CE Mark. This AI-enabled device offers accurate, real-time glucose monitoring and hypoglycemia prediction for diabetes care.


Source:Stock Titan
F. Hoffmann-La Roche Ltd: Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
Jul 08, 2024 15:59pm

The FDA has approved updates to Susvimo, which will be available to US retina specialists and patients with nAMD in the coming weeksSusvimo offers the first alternative to regular eye injections th…


Source:Finanz Nachrichten